Alcon Introduces a Premium, Reusable Toric Lens with Launch of TOTAL30 for Astigmatism
January 05 2023 - 1:05AM
Business Wire
- The first reusable, Water Gradient lens for astigmatic
contact lens wearers
- Reusable toric market is greater than $1.2B and
growing1
- Commercially available in the U.S. and Europe beginning in
early 2023
Alcon (SIX/NYSE: ALC), the global leader in eye care dedicated
to helping people see brilliantly, today announced plans to launch
TOTAL30® for Astigmatism, the first-and-only reusable contact lens
with Water Gradient material for astigmatic contact lens
wearers.
Studies show that comfort plays a critical role in the
lens-wearing experience and brand loyalty of contact lens wearers.2
Using Alcon’s proprietary Water Gradient material first introduced
with DAILIES TOTAL1® contact lenses, TOTAL30 delivers a premium
wearing experience for reusable contact lens wearers.
“Given astigmatic contact lens wearers are more likely to
experience dryness and discomfort, we designed TOTAL30 for
Astigmatism to bring reusable astigmatic lens wearers total
comfort3 and proven stability3,4 for exceptional lens performance,”
said Ian Bell, President of Global Business & Innovation at
Alcon. “These lenses are uniquely designed for reusable patients
with demanding needs and offer Eye Care Professionals Alcon’s
latest innovation to attract contact lens wearers.”
The market for reusable lenses that correct for astigmatism is
currently $1.2 billion and growing.1 Since more patients with
astigmatism wear reusable contact lenses, the availability of
TOTAL30 for Astigmatism not only provides Alcon an opportunity to
gain market share but can also bring exceptional comfort to the
lens-wearing experience of these astigmatic lens wearers.
TOTAL30 for Astigmatism is made with Water Gradient lens
material enabling a gradual increase to nearly 100% water at the
outermost surface so that nothing touches the eye but a gentle
cushion of moisture.5,6 In addition, TOTAL30 features two other
proprietary technologies from Alcon:
- The reusable, Water Gradient design of TOTAL30 for Astigmatism
features biomimetic CELLIGENT™ Technology. CELLIGENT helps resist
bacteria and lipid deposits for a clean lens all month
long.4,8-11
- The PRECISION BALANCE 8|4® lens design provides the on-eye
stability astigmatic contact lens wearers need for exceptionally
clear and stable vision.3
“TOTAL30 has been my go-to lens for patients who prefer reusable
lenses. Now, I can offer the same month-long, premium wearing
experience to astigmatic patients with TOTAL30 for Astigmatism,”
said Danny P. Mathew, O.D., Eyeworks, Texas.* “While many reusable
contact lens wearers think some discomfort is the norm, reusable
toric lens wearers can now experience the excellent comfort of
TOTAL30 for Astigmatism.” 3,7
This is the third lens Alcon has introduced over the past 24
months for the fast-growing toric lens category, including two
daily disposable lenses: DAILIES TOTAL1 for Astigmatism and
PRECISION1® for Astigmatism.
TOTAL30 for Astigmatism will be broadly available in the U.S.
and Europe beginning in early 2023 and the rollout will expand to
more global markets throughout the year.
Rx only. Please see product instructions for full wear, care and
safety information.
Forward-Looking
Statements
This press release contains “forward-looking statements” within
the meaning of the safe harbor provisions of the United States
Private Securities Litigation Reform Act of 1995. Forward-looking
statements can be identified by words such as: “anticipate,”
“intend,” “commitment,” “look forward,” “maintain,” “plan,” “goal,”
“seek,” “target,” “assume,” “believe,” “project,” “estimate,”
“expect,” “strategy,” “future,” “likely,” “may,” “should,” “will”
and similar references to future periods.
Forward-looking statements are neither historical facts nor
assurances of future performance. Instead, they are based only on
our current beliefs, expectations and assumptions regarding the
future of our business, future plans and strategies, and other
future conditions. Because forward-looking statements relate to the
future, they are subject to inherent uncertainties and risks that
are difficult to predict. Some of these factors are discussed in
our filings with the United States Securities and Exchange
Commission, including our Form 20-F. Should one or more of these
uncertainties or risks materialize, or should underlying
assumptions prove incorrect, actual results may vary materially
from those anticipated. Therefore, you should not rely on any of
these forward-looking statements.
Forward-looking statements in this press release speak only as
of the date they are made, and we assume no obligation to update
forward-looking statements as a result of new information, future
events or otherwise.
About Alcon
Alcon helps people see brilliantly. As the global leader in eye
care with a heritage spanning over 75 years, we offer the broadest
portfolio of products to enhance sight and improve people’s lives.
Our Surgical and Vision Care products touch the lives of more than
260 million people in over 140 countries each year living with
conditions like cataracts, glaucoma, retinal diseases and
refractive errors. Our more than 24,000 associates are enhancing
the quality of life through innovative products, partnerships with
Eye Care Professionals and programs that advance access to quality
eye care. Learn more at www.alcon.com.
*Dr. Mathew is a paid Alcon consultant.
References
- Internal calculations; Alcon data on file, 2022.
- Schnider C, Wales M, Canavan K. Evaluating monthly replacement
CL patient satisfaction. Optom Vis Sci. 2016;92:E-abstract
165105.
- In a clinical study wherein patients (n=66) used AOSEPT®
solution for nightly cleaning, disinfecting, and storing; Alcon
data on file, 2021.
- Montaquila S, Gustafson B, Whaley S, Subramanian V. Clinical
performance evaluation of lehfilcon A monthly replacement, silicone
hydrogel toric contact lenses. Optom Vis Sci. 2021;98:E-abstract
215050.
- In vitro analysis of lens oxygen permeability, water content,
and surface imaging; Alcon data on file, 2021.
- In vitro analysis of lehfilcon A contact lenses outermost
surface softness and correlation with water content; Alcon data on
file, 2021.
- In a clinical trial to evaluate stability of axis orientation
of DAILIES TOTAL1® for Astigmatism lenses where n=47; Alcon data on
file, 2020.
- Ishihara K, Fukazawa K, Sharma V, Liang S, et al. Antifouling
silicone hydrogel contact lenses with a bioinspired
2-methacryloyloxyethyl phosphorylcholine polymer surface. ACS
Omega. 2021;6:7058-7067.
- Harris V, Pifer R, Shannon P, Crary M. Low in vitro Pseudomonas
aerunginosa adhesion to lehfilcon A contact lenses. Invest
Ophthalmol Vis Sci. 2022;63:541.
- Pifer R, Harris V, Crary M, Shannon P. Low in vitro Serratia
marcescens adhesion to lehfilcon A contact lenses. Invest
Ophthalmol Vis Sci. 2022;63:541.
- In vitro evaluation of lipid deposition for lehfilcon A and
commercial lenses using 3D confocal imaging; Alcon data on file,
2021.
Connect with us on Facebook LinkedIn
View source
version on businesswire.com: https://www.businesswire.com/news/home/20230104005821/en/
Investor Relations Daniel
Cravens Allen Trang + 41 589 112 110 (Geneva) + 1 817 615 2789
(Fort Worth) investor.relations@alcon.com
Media Relations Steven Smith
+ 41 589 112 111 (Geneva) + 1 817 551 8057 (Fort Worth)
globalmedia.relations@alcon.com
Alcon (NYSE:ALC)
Historical Stock Chart
From Jun 2024 to Jul 2024
Alcon (NYSE:ALC)
Historical Stock Chart
From Jul 2023 to Jul 2024